The Hypertrophic Cardiomyopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypertrophic Cardiomyopathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued products.

GlobalData tracks 40 drugs in development for Hypertrophic Cardiomyopathy by 30 companies/universities/institutes. The top development phase for Hypertrophic Cardiomyopathy is preclinical with 19 drugs in that stage. The Hypertrophic Cardiomyopathy pipeline has 37 drugs in development by companies and three by universities/ institutes. Some of the companies in the Hypertrophic Cardiomyopathy pipeline products market are: Bristol-Myers Squibb, DiNAQOR and Cytokinetics.

The key targets in the Hypertrophic Cardiomyopathy pipeline products market include Myosin, Myosin Binding Protein C Cardiac Type (C Protein Cardiac Muscle Isoform or MYBPC3), and Myosin 7 (Myosin Heavy Chain 7 or Myosin Heavy Chain Slow Isoform or Myosin Heavy Chain Cardiac Muscle Beta Isoform or MYH7).

The key mechanisms of action in the Hypertrophic Cardiomyopathy pipeline product include Myosin Inhibitor with five drugs in Phase III. The Hypertrophic Cardiomyopathy pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Hypertrophic Cardiomyopathy pipeline products market including Small Molecule, and Gene Therapy.

Hypertrophic Cardiomyopathy overview

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise; sensation of rapid, fluttering or pounding heartbeats; and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers, and blood thinners.

For a complete picture of Hypertrophic Cardiomyopathy’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.